查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813988

肝癌诊断市场规模、份额和趋势分析报告：按测试类型、最终用途、地区和细分市场预测，2025-2033 年

Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type, By End-use, By Region And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

肝癌诊断市场摘要

预计 2024 年全球肝癌诊断市场价值将达到 99.9 亿美元，到 2033 年将达到 175.7 亿美元，2025 年至 2033 年的复合年增长率为 6.42%。

肝癌是全球所有致命疾病中死亡的主要原因。

自1980年以来，肝癌发生率增加了两倍，死亡率则翻了一番。美国癌症协会估计，2025年将有约42,240例新病例和30,090例死亡病例。因此，全球肝癌盛行率的上升，加上持续存在的危险因素，可能会显着加速筛检和诊断市场的成长。肝癌发生率的上升推动了对早期癌症诊断的需求，并促使人们努力降低相关危险因子。早期发现，尤其是透过有效的筛检项目，对于减少癌症相关死亡至关重要。总体而言，与延迟发现相比，早期诊断癌症可以将患者存活率提高五到十倍。

随着全球肝癌患者数量的增加，对早期检测工具和筛检方法的需求也日益增长。例如，2025 年 4 月，美国国家癌症研究所建立了肝细胞癌筛检(PDQ) - 医疗保健专业版计划，该计划利用细针抽吸细胞学检查和经子宫颈肝切片检查等技术。该计划重点关注高风险族群，例如患有慢性肝病的人，提高对超音波、 电脑断层扫描和血液检查等诊断工具的认识和使用。早期和定期筛检可提高检出率和患者预后。对预防和早期诊断的日益重视正在推动肝癌诊断的技术创新并加速市场成长。

由于尖端早期筛检技术的不断发展，肝癌筛检和治疗正在发生重大转变。这些新的技术创新为肝癌诊断市场的成长铺平了道路。例如，2025 年 4 月，FDA 授予 EvoLiver切片检查测试突破性医疗设备称号，用于监测肝硬化高风险患者的肝细胞癌 (HCC)。此测试使用基于细胞外囊泡 (EV) 的多体学学生物标记特征，在检测早期 HCC 方面显示出良好的结果。来自包括 464 个患者检体的 MEV01 试验的数据显示，EvoLiver 测试在检测早期 HCC 方面实现了令人印象深刻的 86% 的敏感性和 88% 的特异性。这些结果明显优于超音波和甲胎蛋白检测等目前的监测方法。这种创新方法有可能显着改善肝硬化患者的 HCC 管理。

目录

第一章调查方法与范围

第二章执行摘要

第三章肝癌诊断市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场前景。
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 肝癌诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章肝癌诊断市场：测试类型估计和趋势分析

  • 细分仪表板
  • 肝癌诊断市场：产品差异分析
  • 肝癌诊断市场规模及趋势分析（依检测类型，2021-2033）
    • 2021-2033年全球临床检测市场
    • 影像学
    • 内视镜检查
    • 切片检查

第五章肝癌诊断市场：最终用途估计与趋势分析

  • 2024年和2033年的最终用途市场份额
  • 细分仪表板
  • 全球肝癌诊断市场：依最终用途分類的展望
  • 2021年至2033年市场规模、预测与趋势分析
  • 医院和诊断实验室
    • 2021-2033年全球医院与诊断实验室市场
  • 学术和研究机构
    • 2021-2033年全球学术与研究机构市场
  • 製药/CRO实验室
    • 2021-2033年全球製药和CRO实验室市场

第六章肝癌诊断市场：区域估计与趋势分析

  • 2024 年及 2033 年区域市占率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 市场规模、预测趋势分析，2021-2033年：
  • 北美洲
    • 北美：SWOT分析
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲：SWOT分析
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 亚太地区：SWOT分析
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲：SWOT分析
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • Key customers
    • Key company market share analysis, 2024
    • Abbott Laboratories
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Qiagen NV
    • Siemens Healthineers
    • Becton, Dickinson &Company
    • Illumina, Inc.
    • Epigenomics AG
    • Koninklijke Philips NV
    • Fujifilm Medical Systems USA, Inc.
Product Code: GVR-3-68038-012-5

Liver Cancer Diagnostics Market Summary

The global liver cancer diagnostics market size was estimated at USD 9.99 billion in 2024 and is projected to reach USD 17.57 billion by 2033, growing at a CAGR of 6.42% from 2025 to 2033. Liver cancer is the leading cause of death amongst all deadly diseases in the globe.

Since 1980, the rate of incidence of liver cancer has tripled and death rates have doubled during this period. The American Cancer Society estimated that in 2025, about 42,240 new cases are expected, and about 30,090 people will succumb to death. Thus, the global rise in liver cancer prevalence, combined with ongoing exposure to risk factors, will significantly accelerate the growth of the screening and diagnosis market. The rising incidence of liver cancer is increasing the demand for early-stage cancer diagnosis and efforts to reduce associated risk factors. Early detection is crucial in lowering cancer-related deaths, especially through effective screening programs. Overall, diagnosing cancer early can boost patient survival rates by 5 to 10 times compared to later detection.

As the global cases of liver cancer grow, the need for early detection tools and screening methods has intensified. For instance, the National Cancer Institute established the Liver (Hepatocellular) Cancer Screening (PDQ)-health professional version program in April 2025, utilizing techniques like needle aspiration cytology and trans jugular liver biopsy. Programs focused on high-risk groups, such as those with chronic liver conditions, are promoting greater awareness and use of diagnostic tools like ultrasound, CT scans, and blood tests. Early and regular screenings improve detection rates and patient outcomes. This increased emphasis on prevention and early diagnosis is driving innovations in liver cancer diagnostics and accelerating market growth.

Liver cancer screening and treatment are poised for a major shift thanks to cutting-edge early screening technologies currently in advanced development stages. These new innovations are paving the way for growth in the liver diagnostics market. For instance, in April 2025, the FDA granted breakthrough device designation to the EvoLiver biopsy test for monitoring hepatocellular carcinoma (HCC) in patients with high-risk cirrhosis. The test uses a multiomics biomarker signature based on extracellular vesicles (EV) and has shown promising results in detecting early-stage HCC. Data from the MEV01 trial, which involved 464 patient samples, indicated that the EvoLiver test achieved an impressive 86% sensitivity and 88% specificity for early-stage HCC detection. These results significantly surpass current surveillance methods like ultrasound and alpha-fetoprotein testing. This innovative approach has the potential to improve the management of hepatocellular carcinoma in cirrhotic patients greatly.

Global Liver Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global liver cancer diagnostics market report on the basis of test type, end-use, and region:

  • Test type Outlook (Revenue, USD Million, 2021 - 2033)
  • Laboratory Tests
    • Biomarkers
    • Oncofetal and Glycoprotein Antigens
    • Enzymes and Isoenzymes
    • Growth Factors and Receptors
    • Molecular Markers
    • Pathological Biomarkers
    • Blood Tests
  • Imaging
  • Endoscopy
  • Biopsy
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & CRO Laboratories
  • Regional Outlook (Revenue in USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test type
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test type outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Liver Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Incidence of Liver Cancer
      • 3.2.1.2. Technological Advancements
      • 3.2.1.3. Extensive R&D For Developing Novel Testing Solutions
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Diagnostic imaging
  • 3.3. Liver Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Liver Cancer Diagnostics Market: Test type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Liver Cancer Diagnostics Market: Product Movement Analysis
  • 4.3. Liver Cancer Diagnostics Market Size & Trend Analysis, by test type, 2021 to 2033 (USD Million)
    • 4.3.1. Global Laboratory Tests Market, 2021 - 2033 (USD MILLION)
      • 4.3.1.1. Biomarkers
        • 4.3.1.1.1. Global biomarkers market, 2021 - 2033 (USD million)
          • 4.3.1.1.1.1. Oncofetal and Glycoprotein Antigens
            • 4.3.1.1.1.1.1. Global oncofetal and glycoprotein antigens market, 2021 - 2033 (USD million)
          • 4.3.1.1.1.2. Enzymes and Isoenzymes
            • 4.3.1.1.1.2.1. Global enzymes and isoenzymes market, 2021 - 2033 (USD million)
          • 4.3.1.1.1.3. Growth Factors and Receptors
            • 4.3.1.1.1.3.1. Global growth factors and receptors market, 2021 - 2033 (USD million)
          • 4.3.1.1.1.4. Molecular Markers
            • 4.3.1.1.1.4.1. Global molecular markers market, 2021 - 2033 (USD million)
          • 4.3.1.1.1.5. Pathological Biomarkers
            • 4.3.1.1.1.5.1. Global pathological biomarkers market, 2021 - 2033 (USD million)
      • 4.3.1.2. Blood Tests
        • 4.3.1.2.1. Global blood tests market, 2021 - 2033 (USD million)
    • 4.3.2. Imaging
      • 4.3.2.1. Global Imaging Market, 2021 - 2033 (USD MILLION)
    • 4.3.3. Endoscopy
      • 4.3.3.1. Global Endoscopy Market, 2021 - 2033 (USD MILLION)
    • 4.3.4. Biopsy
      • 4.3.4.1. Global Biopsy Market, 2021 - 2033 (USD MILLION)

Chapter 5. Liver Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Liver Cancer Diagnostics Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Hospitals & Diagnostic Laboratories
    • 5.5.1. Global Hospitals & Diagnostic Laboratories market, 2021 - 2033 (USD Million)
  • 5.6. Academic & Research Institutes
    • 5.6.1. Global Academic & Research Institutes Market, 2021 - 2033 (USD million)
  • 5.7. Pharmaceutical & CRO Laboratories
    • 5.7.1. Global Pharmaceutical & CRO Laboratories market, 2021 - 2033 (USD million)

Chapter 6. Liver Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 6.5. North America
    • 6.5.1. North America: SWOT Analysis
    • 6.5.2. U.S.
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/Reimbursement
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/Reimbursement
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/Reimbursement
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe: SWOT Analysis
    • 6.6.2. UK
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/Reimbursement
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/Reimbursement
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.4. France
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/Reimbursement
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.5. Italy
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/Reimbursement
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.6. Spain
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/Reimbursement
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.7. Norway
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/Reimbursement
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.8. Sweden
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/Reimbursement
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.9. Denmark
      • 6.6.9.1. Key country dynamics
      • 6.6.9.2. Regulatory framework/Reimbursement
      • 6.6.9.3. Competitive scenario
      • 6.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Asia Pacific: SWOT Analysis
    • 6.7.2. Japan
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/Reimbursement
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.3. China
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/Reimbursement
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.4. India
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/Reimbursement
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.5. Australia
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/Reimbursement
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.6. South Korea
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/Reimbursement
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.7. Thailand
      • 6.7.7.1. Key country dynamics
      • 6.7.7.2. Regulatory framework/Reimbursement
      • 6.7.7.3. Competitive scenario
      • 6.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Latin America: SWOT Analysis
    • 6.8.2. Brazil
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/Reimbursement
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/Reimbursement
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.9. MEA
    • 6.9.1. MEA: SWOT Analysis
    • 6.9.2. South Africa
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/Reimbursement
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.9.3. Saudi Arabia
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/Reimbursement
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.9.4. UAE
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/Reimbursement
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.9.5. Kuwait
      • 6.9.5.1. Key country dynamics
      • 6.9.5.2. Regulatory framework
      • 6.9.5.3. Competitive scenario
      • 6.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
    • 7.3.4. Abbott Laboratories
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Services benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Thermo Fisher Scientific, Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Services benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. F. Hoffmann-La Roche Ltd.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Services benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Qiagen N.V.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Services benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Siemens Healthineers
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Services benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Becton, Dickinson & Company
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Services benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Illumina, Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Services benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Epigenomics AG
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Services benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Koninklijke Philips N.V.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Services benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Fujifilm Medical Systems U.S.A., Inc.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Services benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Liver cancer diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 4 North America Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 5 U.S Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 6 U.S Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 7 Canada Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 8 Canada Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 9 Mexico Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 10 Mexico Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 11 Europe Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 12 Europe Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 13 UK Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 14 UK Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Germany Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 16 Germany Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 17 France Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 18 France Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Italy Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 20 Italy Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 21 Spain Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 22 Spain Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 23 Denmark Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 24 Denmark Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 25 Sweden Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 26 Sweden Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 27 Norway Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 28 Norway Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 29 Asia Pacific Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 30 Asia Pacific Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 31 Japan Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 32 Japan Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 33 China Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 34 China Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 35 India Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 36 India Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 37 Australia Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 38 Australia Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 39 South Korea Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 40 South Korea Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 41 Thailand Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 42 Thailand Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Latin America Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 44 Latin America Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 45 Brazil Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 46 Brazil Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 47 Argentina Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 48 Argentina Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 49 MEA Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 50 MEA Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 51 South Africa Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 52 South Africa Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 53 Saudi Arabia Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 54 Saudi Arabia Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 55 UAE Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 56 UAE Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 57 Kuwait Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 58 Kuwait Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Liver cancer diagnostics market: market outlook
  • Fig. 14 Liver cancer diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Liver cancer diagnostics market driver impact
  • Fig. 20 Liver cancer diagnostics market restraint impact
  • Fig. 21 Liver cancer diagnostics market strategic initiatives analysis
  • Fig. 22 Liver cancer diagnostics market: Test type movement analysis
  • Fig. 23 Liver cancer diagnostics market: Test type outlook and key takeaways
  • Fig. 24 Laboratory Tests Liver Cancer Diagnostics market estimates and forecast, 2021 - 2033
  • Fig. 25 Imaging Liver Cancer Diagnostics estimates and forecast, 2021 - 2033
  • Fig. 26 Endoscopy Liver Cancer Diagnostics market estimates and forecast, 2021 - 2033
  • Fig. 27 Biopsy Liver Cancer Diagnostics market estimates and forecast, 2021 - 2033
  • Fig. 28 Others Liver Cancer Diagnostics market estimates and forecast, 2021 - 2033
  • Fig. 29 Liver cancer diagnostics market: End Use movement analysis
  • Fig. 30 Liver cancer diagnostics market: End Use outlook and key takeaways
  • Fig. 31 Hospitals & Diagnostic Laboratories market estimates and forecasts, 2021 - 2033
  • Fig. 32 Academic and Research Institutes market estimates and forecasts, 2021 - 2033
  • Fig. 33 Pharmaceutical & CRO Laboratories market estimates and forecasts, 2021 - 2033
  • Fig. 34 Global Liver cancer diagnostics market: Regional movement analysis
  • Fig. 35 Global Liver cancer diagnostics market: Regional outlook and key takeaways
  • Fig. 36 Global Liver cancer diagnostics market share and leading players
  • Fig. 37 North America market share and leading players
  • Fig. 38 Europe market share and leading players
  • Fig. 39 Asia Pacific market share and leading players
  • Fig. 40 Latin America market share and leading players
  • Fig. 41 Middle East & Africa market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America
  • Fig. 44 North America market estimates and forecasts, 2021 - 2033
  • Fig. 45 U.S.
  • Fig. 46 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 47 Canada
  • Fig. 48 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 49 Mexico
  • Fig. 50 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 51 Europe
  • Fig. 52 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 53 UK
  • Fig. 54 UK market estimates and forecasts, 2021 - 2033
  • Fig. 55 Germany
  • Fig. 56 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 57 France
  • Fig. 58 France market estimates and forecasts, 2021 - 2033
  • Fig. 59 Italy
  • Fig. 60 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 61 Spain
  • Fig. 62 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 63 Denmark
  • Fig. 64 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 65 Sweden
  • Fig. 66 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 67 Norway
  • Fig. 68 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 69 Asia Pacific
  • Fig. 70 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 71 China
  • Fig. 72 China market estimates and forecasts, 2021 - 2033
  • Fig. 73 Japan
  • Fig. 74 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 75 India
  • Fig. 76 India market estimates and forecasts, 2021 - 2033
  • Fig. 77 Thailand
  • Fig. 78 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 79 South Korea
  • Fig. 80 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 81 Australia
  • Fig. 82 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 83 Latin America
  • Fig. 84 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 85 Brazil
  • Fig. 86 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 87 Argentina
  • Fig. 88 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 89 Middle East and Africa
  • Fig. 90 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 91 South Africa
  • Fig. 92 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 93 Saudi Arabia
  • Fig. 94 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 95 UAE
  • Fig. 96 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 97 Kuwait
  • Fig. 98 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 99 Market share of key market players- Liver cancer diagnostics market